Ken Griffin Bio N Tech Se Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bio N Tech Se stock. As of the latest transaction made, Citadel Advisors LLC holds 405,700 shares of BNTX stock, worth $49.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

405,700

Previous 482,200 15.86%

Holding current value

$49.8 Million

Previous $57.3 Million 19.28%

% of portfolio

0.01%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$99.72 - $122.68 $8.83 Million - $10.9 Million	88,527 Added 227.55%	127,431 $14.5 Million
Q3 2024 Nov 14, 2024	SELL	$78.36 - $124.66 $2.14 Million - $3.4 Million	-27,308 Reduced 41.24%	38,904 $4.62 Million
Q2 2024 Aug 14, 2024	SELL	$80.36 - $102.87 $33.2 Million - $42.5 Million	-412,668 Reduced 86.17%	66,212 $5.32 Million
Q1 2024 May 15, 2024	BUY	$88.96 - $112.35 $39.9 Million - $50.4 Million	448,933 Added 1499.09%	478,880 $44.2 Million
Q4 2023 Feb 14, 2024	SELL	$90.91 - $112.75 $2.56 Million - $3.18 Million	-28,199 Reduced 48.5%	29,947 $3.16 Million
Q3 2023 Nov 14, 2023	SELL	$98.5 - $125.08 $13.4 Million - $17 Million	-136,062 Reduced 70.06%	58,146 $6.32 Million
Q2 2023 Aug 14, 2023	BUY	$102.58 - $129.66 $19.2 Million - $24.3 Million	187,519 Added 2803.39%	194,208 $21 Million
Q1 2023 May 15, 2023	SELL	$122.57 - $153.67 $15.4 Million - $19.3 Million	-125,602 Reduced 94.94%	6,689 $833,000
Q4 2022 Feb 14, 2023	BUY	$118.43 - $186.05 $12.9 Million - $20.2 Million	108,750 Added 461.96%	132,291 $19.9 Million
Q3 2022 Nov 14, 2022	SELL	$127.65 - $183.11 $33.7 Million - $48.4 Million	-264,344 Reduced 91.82%	23,541 $3.18 Million
Q2 2022 Aug 15, 2022	BUY	$123.25 - $186.24 $14.4 Million - $21.8 Million	116,888 Added 68.36%	287,885 $42.9 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $8.87 Million - $16.3 Million	-70,295 Reduced 29.13%	170,997 $29.2 Million
Q4 2021 Feb 14, 2022	SELL	$216.64 - $362.52 $7.76 Million - $13 Million	-35,808 Reduced 12.92%	241,292 $62.2 Million
Q3 2021 Nov 15, 2021	BUY	$205.93 - $447.23 $13.3 Million - $28.9 Million	64,532 Added 30.36%	277,100 $75.6 Million
Q2 2021 Aug 16, 2021	BUY	$113.32 - $241.49 $1.65 Million - $3.51 Million	14,535 Added 7.34%	212,568 $47.6 Million
Q1 2021 May 17, 2021	SELL	$85.73 - $119.5 $5.89 Million - $8.21 Million	-68,705 Reduced 25.76%	198,033 $21.6 Million
Q4 2020 Feb 16, 2021	BUY	$72.71 - $129.54 $9.03 Million - $16.1 Million	124,192 Added 87.12%	266,738 $21.7 Million
Q3 2020 Nov 16, 2020	SELL	$57.81 - $104.17 $12.3 Million - $22.1 Million	-212,615 Reduced 59.86%	142,546 $9.87 Million
Q2 2020 Aug 14, 2020	BUY	$38.58 - $66.74 $13.7 Million - $23.7 Million	355,161 New	355,161 $23.7 Million

Others Institutions Holding BNTX

# of Institutions

362

Shares Held

39.6M

Call Options Held

3.01M

Put Options Held

2.01M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $29.8B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account